Signal pathways of melanoma and targeted therapy.

Signal Transduct Target Ther · 2021 · PMC8685279 · PMID 34924562

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

However, adjuvant IFNα-2b showed marginally significant and slightly diminished positive effects on the recurrence-free survival (RFS) and OS of resected stage III melanoma patients, concomitant with intolerable toxicity. 564 , 565 In 2005, adjuvant ipilimumab at a dose of 10 mg/kg resulted in significantly higher rates of RFS and OS, although with high

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.